COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 2 of 3 for:    plurogel

Topical PluroGel N for the Treatment of Mildly Infected Diabetic Foot Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02091596
Recruitment Status : Completed
First Posted : March 19, 2014
Last Update Posted : September 25, 2014
Arkios BioDevelopment International
Information provided by (Responsible Party):
PluroGen Therapeutics, Inc

Brief Summary:
This will be a randomized, double-blind (evaluator-blind), vehicle-controlled study of 50 enrolled subjects. Adult subjects (greater than 18 years old) who present with a mildly infected diabetic foot ulcer (IDSA criteria) having full thickness (i.e., through the dermis but not involving joint capsule, tendon, and bone). Subjects must also provide informed consent and meet all other entry criteria to be enrolled and randomly assigned to receive PluroGel N or PluroGel vehicle.

Condition or disease Intervention/treatment Phase
Diabetic Foot Ulcer Infection Drug: PluroGel N Drug: PluroGel Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Vehicle-controlled 2-Arm Trial of Topical PluroGel N for the Treatment of Patients With Mildly Infected Diabetic Foot Ulcer CLINICAL PROTOCOL PGN-1300
Study Start Date : October 2013
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: PluroGel
Drug: PluroGel
PluroGel Vehicle Placebo Comparator

Experimental: PluroGel N
PluroGel N
Drug: PluroGel N
Study Drug

Primary Outcome Measures :
  1. Clinical Response [ Time Frame: 14 Days ]
    Clinical Response is defined by the investigator's evaluation of the signs and symptoms of clinical infection.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Non-hospitalized subjects with Type 1 or Type 2 diabetes mellitus as defined by the American Diabetes Association diagnostic criteria (ADA, 2010). Diabetes may be treated with insulin, oral hypoglycemic agents, diet, or a combination of these therapies. Subjects whose diabetes is considered "controlled" by diet or medication in the opinion of the physician.

    • Males or females at least 18 years old.
    • Subjects must be considered by the investigator to be reliable, willing and able to give signed informed consent, and must sign the informed consent form.
    • Subjects must have a full thickness (i.e., extending through dermis but not involving tendon, bone, or joint capsule) ulcer on the foot distal to the malleoli with a surface area ≥1 cm2 after the wound has undergone appropriate debridement. Subjects must have localized mild infection of the ulcer, as defined by the IDSA criteria as per Appendix C, with in the PGN1300 Protocol, which the investigator believes would ordinarily be treated on an outpatient basis.

IDSA mild infection of an ulcer is defined as:

The presence of ≥2 of the following items:

  • Local swelling or induration
  • Erythema
  • Local tenderness or pain
  • Local warmth
  • Purulent discharge (thick, opaque to white or sanguineous secretion) Local infection involving only the skin and the subcutaneous tissue. If erythema, must be >0.5 cm to ≤2 cm around the ulcer.

    • Diabetic Foot Infection-General Parameters Score of at least 2 must be obtained in order to be eligible for enrollment.
    • Diabetic Foot Infection-Wound Size Score of at least 1 must be obtained in order to be eligible for enrollment.
    • The diagnosis of mild infection must be confirmed immediately following the Day 0 (Enrollment Visit) debridement, although pre-debridement purulence is to be counted as one manifestation of infection.

Exclusion Criteria:

  • Subjects with IDSA-defined moderate infection as per Appendix C, including cellulitis extending > 2 cm; lymphangitis; spread beneath the fascia; deep tissue abscess; osteomyelitis; gangrene; muscle, joint, or bone involvement.

    • Subjects with IDSA-defined severe infection as per Appendix C, within PGN1300 Protocol including systemic toxicity or metabolic instability (e.g., fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, hyperglycemia, or azotemia).
    • Subjects with systemic inflammatory response signs, as manifested by ≥2 of the following :
  • Temperature >38°C or <36°C
  • Heart rate >90 beats/min
  • Respiratory rate >20 breaths/min or PaCO2 <32 mm Hg
  • White blood cell count >12 000 or <4000 cells/μL or ≥10% immature (band) forms

    • Subjects with local wound complications (e.g., prosthetic materials).
    • Subjects currently receiving antibiotic treatment for a localized infection of the study ulcer and whose infection is improving in response to treatment.
    • Subjects requiring concurrent systemic antimicrobials during the study period for any infection, including diabetic foot ulcer.
    • Subjects in whom bone or joint involvement is suspected based on clinical examination (e.g., bone noted visually or by probing) or plain view X-ray.
    • Subjects with clinically significant peripheral arterial disease requiring vascular reconstructive surgery. Subjects who are expected to be unable to care for their ulcer because of hospitalization, vacation, disability, etc. during the study period, or are unable to safely monitor the infection status at home.
    • Subjects with known active alcohol or substance abuse within the 6 months preceding study entry.
    • Subjects who are receiving immunosuppressive agents (other than corticosteroids), radiation therapy, or cytotoxic agents.
    • Subjects who require treatment for a primary or metastatic malignancy (other than squamous or basal cell carcinoma of the skin).
    • Subjects with a systemically immunocompromising disease, such as acquired immune deficiency syndrome or known human immunodeficiency virus infection.
    • Subjects who have had an unexplained fever or chills during the week prior to enrollment.
    • Subjects with other conditions considered by the investigator to be reasons for disqualification that may jeopardize subject safety or interfere with the objectives of the trial (e.g., acute illness or exacerbation of chronic illness, lack of motivation, history of poor compliance).
    • Subjects with any known allergy or other contraindication to any ingredients in the study products.
    • Women who are breast feeding, pregnant, or not using contraception unless sterile.
    • Subjects who have been taking or expect to be taking any other investigational therapy within the 30 days prior to entry or during enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02091596

Layout table for location information
United States, Arizona
Ledesma Foot and Ankle
Phoenix, Arizona, United States, 85032
United States, California
Foot & Ankle Clinic
Los Angeles, California, United States, 90010
Samuel Merritt University
Oakland, California, United States, 94609
United States, Connecticut
ASAP Urgent-Care
Hamden, Connecticut, United States, 06514
United States, Florida
Sweet Hope Research Specialty, Inc.
Miami Lakes, Florida, United States, 33016
Advance Medical Research Center
Miami, Florida, United States, 33135
Miami Center for Clinical Research, LLC
Miami, Florida, United States, 33144
Unlimited Medical Research, LLC
Miami, Florida, United States, 33144
Phoenix Medical Research, LLC
Miami, Florida, United States, 33165
Med Research of Florida, LCC
Miami, Florida, United States, 33186
United States, Illinois
Weil Foot & Ankle Institute
Des Plaines, Illinois, United States, 60016
United States, Kentucky
Research Integrity
Owensboro, Kentucky, United States, 42303
United States, Pennsylvania
Paddington Testing Company, Inc
Philadelphia, Pennsylvania, United States, 19103
United States, Texas
AllCare Foot & Ankle, PA
Arlington, Texas, United States, 76015
United States, Virginia
Coastal Podiatry Group
Virginia Beach, Virginia, United States, 23464
Sponsors and Collaborators
PluroGen Therapeutics, Inc
Arkios BioDevelopment International
Layout table for additonal information
Responsible Party: PluroGen Therapeutics, Inc Identifier: NCT02091596    
Other Study ID Numbers: PGN-1300
D11AC00020 ( Other Grant/Funding Number: DoD )
First Posted: March 19, 2014    Key Record Dates
Last Update Posted: September 25, 2014
Last Verified: September 2014
Keywords provided by PluroGen Therapeutics, Inc:
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases